UK HTA (health technology assessment) body unimpressed by clinically-effective but "expensive" Exubera inhaled insulin from Pfizer
This article was originally published in Clinica
Executive Summary
Inhaled insulin was today given a provisional thumbs down in the ongoing appraisal of its potential use to treat type 1 and 2 diabetes in the UK's National Health Service, on the basis of its cost. The health technology assessment (HTA) conducted for the National Institute for Health and Clinical Excellence (NICE) is based on a review of Exubera, manufactured by Pfizer. The delivery device is produced by Bespak in the UK and West Pharmaceuticals in the US.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.